TMED1: A Protein Involved in Immune Response and Cell Death (G11018)

Target Name: TMED1

NCBI ID: G11018

TMED1

TMED1: A Protein Involved in Immune Response and Cell Death

TMED1 (Interleukin 1 receptor-like 1 ligand) is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and eyes. It is a member of the interleukin family of cytokines, which are a group of proteins that play a critical role in the immune response. TMED1 has been shown to have various functions, including the regulation of inflammation, immune cell proliferation, and cell death.

One of the key functions of TMED1 is its role in the regulation of inflammation. TMED1 has been shown to play a critical role in the regulation of inflammatory responses, particularly in the regulation of skin inflammation. For example, TMED1 has been shown to reduce the production of inflammatory cytokines in response to skin damage, such as UV radiation or chemical irritants. It has also been shown to improve the anti-inflammatory response of immune cells, such as natural killer cells and macrophages, to skin damage.

Another function of TMED1 is its role in the regulation of immune cell proliferation. TMED1 has been shown to promote the proliferation of immune cells, particularly natural killer cells and T-cells. This is important for the immune system to mount an effective response to infections and other harmful substances that enter the body. TMED1 has also been shown to regulate the death of immune cells, which is important for maintaining the diversity and functionality of the immune system.

In addition to its role in inflammation and immune cell proliferation, TMED1 has also been shown to play a critical role in the regulation of cell death. TMED1 has been shown to promote the survival of immune cells, particularly natural killer cells, and to protect them from programmed cell death. This is important for maintaining the diversity and functionality of the immune system, and for ensuring that the immune system is able to respond effectively to infections and other harmful substances.

TMED1 has also been shown to play a critical role in the regulation of stem cell proliferation and differentiation. TMED1 has been shown to promote the proliferation of stem cells, particularly human embryonic stem cells, and to influence their differentiation into different cell types. This is important for the development of new treatments for a variety of diseases, including cancer, and for the creation of replacement tissues and organs.

In conclusion, TMED1 is a protein that has been shown to play a critical role in the regulation of inflammation, immune cell proliferation, and cell death. As a result, TMED1 is a potential drug target or biomarker for a variety of diseases. For example, TMED1 has been shown to be a potential therapeutic for a variety of skin cancers, including melanoma, and to have anti-inflammatory effects that could be useful in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Further research is needed to fully understand the functions of TMED1 and to develop effective treatments for a variety of diseases.

Protein Name: Transmembrane P24 Trafficking Protein 1

Functions: Potential role in vesicular protein trafficking, mainly in the early secretory pathway. May act as a cargo receptor at the lumenal side for incorporation of secretory cargo molecules into transport vesicles and may be involved in vesicle coat formation at the cytoplasmic side. Plays a positive role in IL-33-mediated IL-8 and IL-6 production by interacting with interleukin-33 receptor IL1RL1 (PubMed:23319592). Also plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26 (PubMed:32614325)

The "TMED1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMED1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets